Self-assembled DNA nanoparticles loaded with Travoprost for Glaucoma-treatment
Standard
Self-assembled DNA nanoparticles loaded with Travoprost for Glaucoma-treatment. / Schnichels, Sven; Hurst, José; de Vries, Jan Willem; Ullah, Sami; Gruszka, Agnieszka; Kwak, Minseok; Löscher, Marina; Dammeier, Sascha; Bartz-Schmidt, Karl-Ulrich; Spitzer, Martin S; Herrmann, Andreas.
in: NANOMED-NANOTECHNOL, Jahrgang 29, 10.2020, S. 102260.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Self-assembled DNA nanoparticles loaded with Travoprost for Glaucoma-treatment
AU - Schnichels, Sven
AU - Hurst, José
AU - de Vries, Jan Willem
AU - Ullah, Sami
AU - Gruszka, Agnieszka
AU - Kwak, Minseok
AU - Löscher, Marina
AU - Dammeier, Sascha
AU - Bartz-Schmidt, Karl-Ulrich
AU - Spitzer, Martin S
AU - Herrmann, Andreas
N1 - Copyright © 2020 Elsevier Inc. All rights reserved.
PY - 2020/10
Y1 - 2020/10
N2 - Lipid DNA nanoparticles (NPs) exhibit an intrinsic affinity to the ocular surface and can be loaded by hybridization with fluorophore-DNA conjugates or with the anti-glaucoma drug travoprost by hybridizing an aptamer that binds the medication. In the travoprost-loaded NPs (Trav-NPs), the drug is bound by specific, non-covalent interactions, not requiring any chemical modification of the active pharmaceutical ingredient. Fluorescently labeled Trav-NPs show a long-lasting adherence to the eye, up to sixty minutes after eye drop instillation. Biosafety of the Trav-NPs was proved and in vivo. Ex vivo and in vivo quantification of travoprost via LC-MS revealed that Trav-NPs deliver at least twice the amount of the drug at every time-point investigated compared to the pristine drug. The data successfully show the applicability of a DNA-based drug delivery system in the field of ophthalmology for the treatment of a major retinal eye disease, i.e. glaucoma.
AB - Lipid DNA nanoparticles (NPs) exhibit an intrinsic affinity to the ocular surface and can be loaded by hybridization with fluorophore-DNA conjugates or with the anti-glaucoma drug travoprost by hybridizing an aptamer that binds the medication. In the travoprost-loaded NPs (Trav-NPs), the drug is bound by specific, non-covalent interactions, not requiring any chemical modification of the active pharmaceutical ingredient. Fluorescently labeled Trav-NPs show a long-lasting adherence to the eye, up to sixty minutes after eye drop instillation. Biosafety of the Trav-NPs was proved and in vivo. Ex vivo and in vivo quantification of travoprost via LC-MS revealed that Trav-NPs deliver at least twice the amount of the drug at every time-point investigated compared to the pristine drug. The data successfully show the applicability of a DNA-based drug delivery system in the field of ophthalmology for the treatment of a major retinal eye disease, i.e. glaucoma.
U2 - 10.1016/j.nano.2020.102260
DO - 10.1016/j.nano.2020.102260
M3 - SCORING: Journal article
C2 - 32629041
VL - 29
SP - 102260
JO - NANOMED-NANOTECHNOL
JF - NANOMED-NANOTECHNOL
SN - 1549-9634
ER -